Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €26.45 EUR
Change Today +0.201 / 0.77%
Volume 5.7M
CLS1 On Other Exchanges
Symbol
Exchange
Xetra
OTC US
OTC US
As of 3:35 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

celesio ag (CLS1) Snapshot

Open
€26.17
Previous Close
€26.25
Day High
€26.73
Day Low
€26.02
52 Week High
03/9/15 - €28.26
52 Week Low
10/16/14 - €24.70
Market Cap
5.4B
Average Volume 10 Days
765.2K
EPS TTM
€1.16
Shares Outstanding
203.2M
EX-Date
08/12/15
P/E TM
22.8x
Dividend
€0.83
Dividend Yield
1.13%
Current Stock Chart for CELESIO AG (CLS1)

Related News

No related news articles were found.

celesio ag (CLS1) Related Businessweek News

No Related Businessweek News Found

celesio ag (CLS1) Details

Celesio AG provides logistics and services to the pharmaceutical and healthcare sectors worldwide. The company operates through two divisions, Consumer Solutions and Pharmacy Solutions. The Consumer Solutions division offers prescription and a range of over the counter pharmaceutical products. The Pharmacy Solutions division is involved in the wholesale of pharmaceutical products. It offers oncological products and other medicines for the treatment of complex diseases; and provides supplementary services for pharmacists, such as the organization and management of pharmacy cooperation programs. As of March 11, 2015, it served its customers through approximately 2,200 owned pharmacies and approximately 4,300 participants in its brand partnership schemes; and operated approximately 133 wholesale branches that supplied pharmaceutical products to approximately 65,000 pharmacies and hospitals. The company was founded in 1835 and is headquartered in Stuttgart, Germany. Celesio AG operates as a subsidiary of Dragonfly GmbH & Co. KGaA.

29,123 Employees
Last Reported Date: 03/17/15
Founded in 1835

celesio ag (CLS1) Top Compensated Officers

Chairman of the Management Board, Chief Opera...
Total Annual Compensation: €698.0K
Chief Financial Officer and Member of the Man...
Total Annual Compensation: €383.0K
Group Legal Director, Group Compliance Office...
Total Annual Compensation: €198.0K
Compensation as of Fiscal Year 2014.

celesio ag (CLS1) Key Developments

Celesio Put Its Businesses For Sale

Celesio AG (DB:CLS1) said that it would put its businesses in Brazil up for sale to allow it to focus on Europe. The assets include Panpharma and Oncoprod, Celesio said in a statement. "In selling its Brazilian operations, Celesio will increase its focus on European markets and customers," Celesio said.

Celesio AG Reports Earnings Results for the Full Year of 2014; Announces Dividend for the Fiscal Year 2014; Provides Earnings Guidance for the Fiscal 2015 and 2016

Celesio AG reported earnings results for the full year of 2014. For the period, the company reported revenue of €22,325.9 million, EBITDA of €487.4 million, adjusted EBITDA of €532.2 million, EBIT of €237.0 million, adjusted EBIT of €410.9 million, net profit of €52.9 million, adjusted net profit of €216.6 million, earnings were €0.25 per share against revenue of €21,407.7 million, EBITDA of €532.8 million, adjusted EBITDA of €548.6 million, EBIT of €406.6 million, adjusted EBIT of €423.6 million, net profit of €171.2 million, adjusted net profit of €186.4 million, earnings were €0.94 per share a year ago. The company announced guaranteed dividend amounting to €0.83 for the fiscal year 2014. In addition to cost structures, the company will also continue optimizing the efficiency of its companies. However, the development of the upcoming short fiscal 2015 will be burdened by government intervention in several markets accompanied by special effects from the integration process and the ongoing challenging environment in Germany, in Brazil, in France and in Belgium. Therefore the Management Board expects revenue to increase moderately, and adjusted EBIT to be slightly below the unaudited figures for the first quarter 2014. Overall, the company assumes that both revenue and adjusted EBIT for fiscal 2016 will return to the level of fiscal 2014.

Celesio AG Announces Revenue Results for the Year 2014

Celesio AG announced revenue results for the year 2014. For the period, the company generated group revenue of EUR 22,325.9 million, up 4.3% year-on-year. When adjusted for currency effects, revenue increased by 4.2%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLS1:GR €26.45 EUR +0.201

CLS1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cardinal Health Inc $88.17 USD +0.06
McKesson Corp $237.23 USD -0.61
UDG Healthcare PLC 530.50 GBp -4.50
Walgreens Boots Alliance Inc $85.84 USD -0.21
View Industry Companies
 

Industry Analysis

CLS1

Industry Average

Valuation CLS1 Industry Range
Price/Earnings 96.2x
Price/Sales 0.2x
Price/Book 1.8x
Price/Cash Flow 28.4x
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELESIO AG, please visit www.celesio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.